Gutly vs Aidy for UC: AI FODMAP Tools or IBD Tracking?
By the Aidy Editorial Team
First Published May 10, 2026Last Updated Aug 19, 2026
Gutly's listing centers FODMAP tools; Aidy connects the broader UC care picture. Gutly's listing claims FODMAP estimates, AI correlations, and a GutScore. Aidy connects disease activity, treatment, and reports. Their scores answer different questions.
Quick answer: For most people with UC, choose Aidy for a free primary record with treatment, SCCAI trends, and clinician reports. Gutly is the genuine exception for a focused food investigation using its claimed photo or barcode capture, FODMAP estimates, and GutScore.
| Decision factor | Aidy | Gutly (public claims) |
|---|---|---|
| Best for | Complete UC record | Claims AI food investigation |
| Daily IBD record | Food, stool, symptoms, treatment | Claims meals, mood, stress, fiber |
| Treatment tools | Medicines and biologics | Claims no comparable workflow |
| Reports and insights | SCCAI and reports | Claims estimates, GutScore, PDF |
| Access and cost | Free | Claims paid Gutly Plus |
| Overall pick | Aidy | Food-question exception |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
Gutly specializes in food capture and functional symptoms
Any current Gutly app review should credit its convenient logging. The official U.S. App Store listing describes meal entry by photo, barcode, or note, plus symptom, mood, stress, fiber, and Bristol Stool Scale tracking. The same listing says GutAI looks for food-symptom patterns, Prof Gut answers questions, and daily or weekly summaries feed a proprietary visual GutScore. It also claims users can export a PDF for a doctor or dietitian.
Gutly's recent release notes say AI-analyzed ingredients show FODMAP status when reliable database values are available, and users can correct nutrition values. Treat the scanner output as an editable estimate. Gutly's terms say AI output may be incomplete, imprecise, or context-dependent. Its GutScore is an app-generated wellness summary, separate from the validated SCCAI used for initial UC symptom assessment.
A FODMAP app for UC has a narrower clinical role
Low-FODMAP tools can be helpful when a person with controlled or mildly active IBD still has IBS-like symptoms. A meta-analysis of nine studies involving 446 participants found improvements in functional gastrointestinal symptoms and quality of life, but no improvement in the UC Mayo score, stool consistency, or fecal calprotectin. The British Dietetic Association consensus rates the evidence for symptom improvement as very low quality and recommends dietitian-led, short-term restriction followed by reintroduction and personalization when persistent symptoms occur without inflammation.
A randomized trial enrolled 52 people with quiescent IBD and persistent gut symptoms, which shows how specific the intended use case is. Food associations also require caution. The National Institute of Diabetes and Digestive and Kidney Diseases says researchers have not found that specific foods worsen UC, although a food diary may help identify foods that seem related to symptoms. Gutly can organize a diet experiment, but correlations cannot diagnose a flare or prove inflammation is controlled.
Aidy goes deeper on UC activity and treatment
Aidy covers meals, symptoms, stools, medication adherence, food-symptom correlations, trend charts, doctor-ready reports, and automatic Simple Clinical Colitis Activity Index (SCCAI) trends for UC. The original SCCAI validation study found that its five clinical criteria correlated strongly with more complex disease-activity measures, making it a useful initial symptom assessment.
Treatment tools create the larger difference. Aidy supports induction and maintenance schedules for named biologics and biosimilars, reminders, injection-site rotation, adherence history, and post-dose check-ins. Its AI chat is educational, personalized to logged data, source-backed, and outside the role of medical advice. Those features make Aidy the stronger ulcerative colitis AI tracker for maintaining one longitudinal UC record. App scores still have limits: the American Gastroenterological Association recommends symptom-and-biomarker monitoring over symptoms alone during remission.
Gutly Plus price, privacy, and platform access
Gutly is free to download, with Plus listed at $8.99 monthly or $71.99 yearly. Its terms confirm an auto-renewing subscription and possible trial. The public page does not map features to tiers, so check the live paywall.
Aidy is free with no paid user subscriptions, ads, or installation required for its text-message option. That free access covers the continuing IBD record, including reports and treatment logistics.
Both apps are iPhone-first. Apple lists Gutly as requiring iOS 26, while its site claims Android is coming; Aidy requires iOS 15.1 and offers SMS. Apple's labels say Gutly and Aidy may link health and identity data. Gutly's privacy policy covers AI processing of selected photos and records.
Which one fits an everyday UC record?
Gutly is the better specialist tool for rapid barcode or photo logging, fiber estimates, mood and stress context, and a clinician-guided low-FODMAP experiment. Its visual feedback may suit someone with persistent functional symptoms during stable disease. For active UC monitoring, its IBS framing and proprietary GutScore leave treatment context to another system.
Aidy connects food and stool logs with SCCAI trends, medication adherence, biologic schedules, post-dose notes, and clinician-ready reports. That makes it the stronger primary record for UC. As a Gutly alternative, it offers broader IBD depth with free access. The practical choice is Gutly for a focused dietary investigation and Aidy for ongoing UC management, with symptoms, biomarkers, and clinical review interpreted together.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.